The Deans of Johns Hopkins and Miami discuss ACO’s

By Steven Greer, MD

Dean Miller of Johns Hopkins and Dean Goldschmidt of Miami discuss accountable care organizations, or ACO’s. The new ACA healthcare law will mandate academic medical centers to form new groups of doctors and Read more »

What Steve Jobs would have invented if he had lived longer

Update January 29, 2014- Apple posted Q4 earnings so big that they are incomprehensible. Read more »

Using Afrezza inhaled insulin with a CGM

November 3, 2014- Interviewed by Steven E. Greer, MD

Inhaled insulin will make a comeback when Read more »

Hacking CGM’s to smartphones

October 31, 2014- Interviewed by Steven E. Greer, MD

Type 1 diabetes patients using continuous glucose monitors have been creating their own software, or hacking, to allow their CGM to send the data to a more manageable smartphone. This allows parents and other parties to monitor the health of loved ones, as well as makes the data more easily available to see on Read more »

The clinical hurdles to prescribing CGM

October 31, 2014- Interviewed by Steven E. Greer, MD

The portion of total Type 1 diabetes patients who use continuous glucose monitors (CGM) are still far less than 50%. We interviewed  the CEO of Dexcom, Terry Gregg, with diabetes expert Jay Skyler, MD, from Miami, to discuss the clinical hurdles to prescribing CGM.

Disclaimer: Dr. Skyler has various relationships with Dexcom.

Super rapid acting insulin and inhaled insulin

Interviewed by Steven E. Greer, MD

Jay Skyler, MD, PhD, Deputy Director of the Diabetes Research Institute at The University of Miami, and Chairman of the NIH’s TrialNet, discusses the “prandial problem” that requires “super rapid acting” insulin, and some new insulins in clinical trials, including inhaled Afrezza.

Disclosure: Jay Skyler, MD, has disclosed the following relevant financial relationships:
Served as an advisor/consultant for: Sanofi-Aventis; Gilead Sciences, Inc., Merck & Co., Inc.; Takeda Pharmaceuticals North America, Inc.; Cebix, Incorporated; Lilly USA, LLC, Dr. Skyler is an unpaid member of the scientific advisory board of MannKind

Received grants for clinical research from: Halozyme Therapeutics; Intuity Medical, Inc.; Mesoblast Limited; Osiris Therapeutics, Inc.

Owns stocks, stock options, or bonds from: Dexcom, Inc.; Amylin Pharmaceuticals, Inc.; Moerae Matrix; Opko Health Inc.; Patton Medical Devices, LP

Jay Skyler discusses the recent bionic pancreas data

June 22, 2014- By Steven E. Greer, MD

This week, the mainstream press reported on the “bionic pancreas” data published in the NEJM by a group from Boston University and Harvard. Last September, The Healthcare Channel interview Jay Skyler, MD, PhD, an NIH researcher and Type-1 diabetes expert, about this very same program. At the 5:00 mark of the video, Dr. Skyler discusses the bionic pancreas.

The Miami Summit on Healthcare Spending Reduction

June 29, 2010

Produced and interviewed by Steven Greer, MD

CurrentMedicine.TV and The University of Miami Health System hosted a roundtable discussion on the general topic of ways to reduce the growth of healthcare spending. With the passage of the healthcare insurance coverage expansion law, or Affordable Care Act  (ACA), in order to make the plan budget neutral, at least $500 Billion in healthcare spending will need to be trimmed just to reduce the growth rate. Nothing like that has ever been accomplished by the Federal government.

The panel of experts were:

• Donna Shalala, PhD, President of The University of Miami and former Secretary of the Health and Human Services Department for eight years under the Clinton administration.
• Pascal Goldschmidt, MD, Dean of The Miller School of Medicine, The University of Miami, and CEO of the UM health System
• Ralph Sacco, MD, Chair of the Department of Neurology, The Miller School of Medicine, The University of Miami
• David Cutler, PhD, Professor of Applied Economics, Department of Economics and Kennedy School of Government, Harvard University, and senior adviser to President Obama on health policy
• Steven Greer, MD, moderator

In Part 1, The following topics were discussed:

• Pharmaceutical price negotiations by Medicare, the VA, and other Federal agencies
• How PBM’s do not pass along to the payer the rebates they negotiate on drug prices
• Durable medical goods pricing
• The increase in the Medicaid population under the ACA and the stresses to State budgets
• The Medicare “Doctor Fix”
• Cuts to Medicare Advantage
• Cuts to oncology practices
• How the ACA healthcare reform will not decrease spending overall, but rather slow growth

If you do not see the embedded video below, click here

Updates on new therapies for Type 1 diabetes

Interviewed by Steven E. Greer, MD

Jay Skyler, MD, PhD, Deputy Director of the Diabetes Research Institute at The University of Miami, and Chairman of the NIH’s TrialNet, discusses the latest clinical research on Type 1 diabetes. He discusses in-depth the ongoing efforts to create the “artificial pancreas” closed loop system.

Disclosure: Jay Skyler, MD, has disclosed the following relevant financial relationships:
Served as an advisor/consultant for: Sanofi-Aventis; Gilead Sciences, Inc., Merck & Co., Inc.; Takeda Pharmaceuticals North America, Inc.; Cebix, Incorporated; Lilly USA, LLC, Dr. Skyler is an unpaid member of the scientific advisory board of MannKind

Received grants for clinical research from: Halozyme Therapeutics; Intuity Medical, Inc.; Mesoblast Limited; Osiris Therapeutics, Inc.

Owns stocks, stock options, or bonds from: Dexcom, Inc.; Amylin Pharmaceuticals, Inc.; Moerae Matrix; Opko Health Inc.; Patton Medical Devices, LP

Cardiology genomic, stem cell, and interventional research at U. Miami

The Healthcare Channel hosted, in conjunction with Mark Schoenebaum of ISI, a tour of the University of Miami medical center campus. A panel of world leaders in cardiology gave an overview of the latest in stem cell regeneration of myocardial infarction, genomics, and interventional procedures.

In Part 1, Dean Goldschmidt introduces the faculty.

In Part 2, Dr. O’Neill leads of the discussion with an overview of research at Miami.